ibudilast

Small moleculeexperimental

Ibudilast is an anti-inflammatory drug used mainly in Japan, which acts as a phosphodiesterase inhibitor, inhibiting the PDE4 subtype to the greatest extent, but also showing significant inhibition of other PDE subtypes. — Wikipedia

Clinical trial activity

23 trials · 27 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Sep 1, 2006 (NCT00576277)

Timeline

2000s

Jan 1, 2006
Earliest Phase 1 Sponsor(trial)
Jan 1, 2008
Earliest Phase 2 Sponsor(trial)

2020s

Jan 1, 2020
Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Phosphodiesterase 3AINHIBITOR
Phosphodiesterase 3A inhibitor
Also active against PDE11.
- cGMP-inhibited 3',5'-cyclic phosphodiesterase A (PDE3A) ↗
Phosphodiesterase 5AINHIBITOR
Phosphodiesterase 5A inhibitor
Also active against PDE11.
- cGMP-specific 3',5'-cyclic phosphodiesterase (PDE5A) ↗
Phosphodiesterase 10AINHIBITOR
Phosphodiesterase 10A inhibitor
Also active against PDE11.
- cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A) ↗
Phosphodiesterase 4INHIBITOR
Phosphodiesterase 4 inhibitor
Also active against PDE11.
Phosphodiesterase 4BINHIBITOR
PDE4B inhibitor
- cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)C(=O)c1c(C(C)C)nn2ccccc12

Mol. weight: 230.31 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Oral

Oral

Yes

Parenteral

Topical

Sources

WikipediaIbudilast ↗
ChEMBLCHEMBL19449 ↗

Also known as

3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine
av411
av411
av-411
av-411
ibudilast
ibudilast
ibudilast
ibudilast
ibudilast
ibudilast
ibudilast
ibudilast
ibudilastum
ibudilastum
kc 404
kc-404
ketas
ketas
ketas
ketas
ketas
kp-305
mn-166
mn-166
mn-166

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT05513560	Phase 2/Phase 3 (Phase 3)	Jan 31, 2023	University of Oxford, University of Toronto
NCT05414240	Phase 2	Dec 1, 2022	University of Pennsylvania
NCT04631471	Phase 3	Dec 1, 2020	University of Cambridge
NCT04429555	Phase 2	Jul 31, 2020	MediciNova
NCT04057898	Phase 2/Phase 3 (Phase 3)	Oct 31, 2019	MediciNova
NCT04054206	Phase 1	Jun 24, 2019	Collaborative Neuroscience Network, MediciNova
NCT03782415	Phase 1/Phase 2 (Phase 2)	Dec 29, 2018	Harvard University, MediciNova
NCT03341078	Phase 2	Sep 30, 2018	Department of Veteran Affairs, Oregon Health and Science University
NCT03594435	Phase 2	Sep 30, 2018	MediciNova, National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of California, Los Angeles
NCT03489850	Phase 2	Jul 16, 2018	University of California, Los Angeles
NCT03533387	Phase 1	Apr 11, 2018	MediciNova
NCT02714036	Phase 1/Phase 2 (Phase 2)	Mar 1, 2016	Harvard University, MediciNova, South Shore Neurologic Associates
NCT02238626	Phase 2	Sep 1, 2014	MediciNova, University of Florida
NCT02025998	Phase 1	Dec 1, 2013	National Institute on Alcohol Abuse and Alcoholism (NIAAA), University of California, Los Angeles
NCT01982942	Phase 2	Nov 1, 2013	MediciNova, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), National Multiple Sclerosis Society, University of Rochester
NCT01860807	Phase 2	Jul 1, 2013	National Institute on Drug Abuse (NIDA), University of California, Los Angeles
NCT01389193	Phase 1	Jun 1, 2013	Aalborg University, Government of Denmark, Migraine Research Foundation, University of Adelaide
NCT01740414	Phase 2	Nov 1, 2012	Columbia University, MediciNova, National Institute on Drug Abuse (NIDA)
NCT01317992	Phase 1/Phase 2 (Phase 2)	Apr 1, 2011	University of Adelaide, University of South Australia
NCT01217970	Phase 1	Jan 1, 2011	MediciNova, National Institute on Drug Abuse (NIDA), University of California, Los Angeles

Showing 20 of 23 trials

Page 1 / 2

Organizations

Research & Development (27)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
MediciNova	For profit	12	8	4	2011
University of California, Los Angeles	Academic/Hospital	5	5	2	2011
National Institute on Drug Abuse (NIDA)	Government	4	0	2	2008
Columbia University	Academic/Hospital	2	2	1	2008
Harvard University	Academic/Hospital	2	0	1	2016
National Institute of Neurological Disorders and Stroke (NINDS)	Government	2	0	2	2013
National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Government	2	0	2	2013
University of Adelaide	Academic/Hospital	2	1	2	2011
Aalborg University	Academic/Hospital	1	1	1	2013
Avigen	For profit	1	1	1	2006
Collaborative Neuroscience Network	For profit	1	0	1	2019
Department of Veteran Affairs	Government	1	0	1	2018
Government of Denmark	Government	1	0	1	2013
Mayo Clinic	Academic/Hospital	1	1	1	—
Migraine Research Foundation	Academic/Hospital	1	0	1	2013
National Institutes of Health (NIH)	Government	1	0	1	2013
National Multiple Sclerosis Society	Academic/Hospital	1	0	1	2013
Oregon Health and Science University	Academic/Hospital	1	1	1	2018
South Shore Neurologic Associates	Academic/Hospital	1	0	1	2016
University of Cambridge	Academic/Hospital	1	1	1	2020

27 organizations

Page 1 / 2